M2 Macrophage Classification of Colorectal Cancer Reveals Intrinsic Connections with Metabolism Reprogramming and Clinical Characteristics

References

• Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA a Cancer J Clinicians. 2023;73(3):233–254. doi:10.3322/caac.21772
   PubMed Web of Science ®Google Scholar
• Mazzoccoli G. Colorectal cancer prognosis and PPARd/b expression in the tumor microenvironment. J Gastroenterol. 2014;49(3):564–565. doi:10.1007/s00535-013-0913-z
   PubMed Web of Science ®Google Scholar
• Lepski G, Bergami-Santos PC, Pinho MP, et al. Adjuvant vaccination with allogenic dendritic cells significantly prolongs overall survival in high-grade gliomas: results of a phase II Trial. Cancers. 2023;15(4):1239. doi:10.3390/cancers15041239
   PubMed Web of Science ®Google Scholar
• Bloemendal M, Bol KF, Boudewijns S, et al. Immunological responses to adjuvant vaccination with combined CD1c + myeloid and plasmacytoid dendritic cells in stage III melanoma patients. OncoImmunology. 2022;11(1):2015113. doi:10.1080/2162402X.2021.2015113
   PubMed Web of Science ®Google Scholar
• Kang Y-K, Chen L-T, Ryu M-H, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, Phase 3 trial. Lancet Oncol. 2022;23(2):234–247. doi:10.1016/S1470-2045(21)00692-6
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. doi:10.1016/S0140-6736(21)00797-2
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437. doi:10.1038/nm.3394
   PubMed Web of Science ®Google Scholar
• Jin M-Z, Jin W-L. The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020;5(1):166. doi:10.1038/s41392-020-00280-x
   PubMed Web of Science ®Google Scholar
• Duan Q, Zhang H, Zheng J, Zhang L. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer. 2020;6(7):605–618. doi:10.1016/j.trecan.2020.02.022
   PubMed Web of Science ®Google Scholar
• Zhao X, Qu J, Sun Y, et al. Prognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature. Oncotarget. 2017;8(18):30576–30586. doi:10.18632/oncotarget.15736
   PubMedGoogle Scholar
• Yu M, Guan R, Hong W, et al. Prognostic value of tumor-associated macrophages in pancreatic cancer: a meta-analysis. Cancer Manag Res. 2019;11:4041–4058. doi:10.2147/CMAR.S196951
   PubMed Web of Science ®Google Scholar
• Zhang J, Chang L, Zhang X, Zhou Z, Gao Y. Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in hepatocellular carcinoma. J Invest Surg. 2021;34(3):297–306. doi:10.1080/08941939.2019.1631411
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhang M, Peng R, et al. The prognostic and clinicopathological value of tumor-associated macrophages in patients with colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2020;35(9):1651–1661. doi:10.1007/s00384-020-03686-9
   PubMed Web of Science ®Google Scholar
• Fakih M, Ouyang C, Wang C, et al. Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome. J Clin Invest. 2019;129(10):4464–4476. doi:10.1172/JCI127046
   PubMed Web of Science ®Google Scholar
• Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009;27(1):451–483. doi:10.1146/annurev.immunol.021908.132532
   PubMed Web of Science ®Google Scholar
• Han Y, Sun J, Yang Y, et al. TMP195 exerts antitumor effects on colorectal cancer by promoting m1 macrophages polarization. Int J Biol Sci. 2022;18(15):5653–5666. doi:10.7150/ijbs.73264
   PubMed Web of Science ®Google Scholar
• Wang H, Tian T, Zhang J. Tumor-associated macrophages (TAMs) in colorectal cancer (CRC): from mechanism to therapy and prognosis. Int J Mol Sci. 2021;22(16):8470. doi:10.3390/ijms22168470
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34(3):355–377. doi:10.1016/j.cmet.2022.01.007
   PubMed Web of Science ®Google Scholar
• Tennant DA, Durán RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer. 2010;10:267–277.
   PubMed Web of Science ®Google Scholar
• Oliveira PF, Martins AD, Moreira AC, Cheng CY, Alves MG. The Warburg effect revisited--lesson from the Sertoli cell. Med Res Rev. 2015;35(1):126–151. doi:10.1002/med.21325
   PubMed Web of Science ®Google Scholar
• Li M, et al. Metabolism, metabolites, and macrophages in cancer. J Hematol Oncol. 2023;16(1):80. doi:10.1186/s13045-023-01478-6
   PubMed Web of Science ®Google Scholar
• Liu S, Shen YY, Yin LY, Liu J, Zu X. Lipid metabolic regulatory crosstalk between cancer cells and tumor-associated macrophages. DNA Cell Biol. 2023;42(8):445–455. doi:10.1089/dna.2023.0071
   PubMed Web of Science ®Google Scholar
• Yu L, et al. Macrophage-to-endothelial cell crosstalk by the cholesterol metabolite 27HC promotes atherosclerosis in male mice. Nat Commun. 2023;14(1):4101. doi:10.1038/s41467-023-39586-z
   PubMed Web of Science ®Google Scholar
• Szeglin BC, Wu C, Marco MR, et al. A SMAD4 -modulated gene profile predicts disease-free survival in stage II and III colorectal cancer. Cancer Rep. 2022;5(1):e1423. doi:10.1002/cnr2.1423
   Google Scholar
• Tripathi MK, et al. Nuclear factor of activated T-cell activity is associated with metastatic capacity in colon cancer. Cancer Res. 2014;74(23):6947–6957. doi:10.1158/0008-5472.CAN-14-1592
   PubMed Web of Science ®Google Scholar
• Uhlitz F, Bischoff P, Peidli S, et al. Mitogen-activated protein kinase activity drives cell trajectories in colorectal cancer. EMBO Mol Med. 2021;13(10):e14123. doi:10.15252/emmm.202114123
   PubMed Web of Science ®Google Scholar
• Andreatta M, Carmona SJ. UCell: robust and scalable single-cell gene signature scoring. Comput Struct Biotechnol J. 2021;19:3796–3798. doi:10.1016/j.csbj.2021.06.043
   PubMed Web of Science ®Google Scholar
• Yang J, Wei H, Zhou Y, et al. High-fat diet promotes colorectal tumorigenesis through modulating gut microbiota and metabolites. Gastroenterology. 2022;162(1):135–149.e2. doi:10.1053/j.gastro.2021.08.041
   PubMed Web of Science ®Google Scholar
• Jin B-R, Chung K-S, Lee M, An H-J. High-fat diet propelled AOM/DSS-induced colitis-associated colon cancer alleviated by administration of aster glehni via STAT3 signaling pathway. Biology. 2020;9(2):24. doi:10.3390/biology9020024
   PubMedGoogle Scholar
• Bossard C, Bézieau S, Matysiak‐Budnik T, et al. HLA-E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression. Int J Cancer. 2012;131(4):855–863. doi:10.1002/ijc.26453
   PubMed Web of Science ®Google Scholar
• Tirier SM, Mallm J-P, Steiger S, et al. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. Nat Commun. 2021;12(1):6960. doi:10.1038/s41467-021-26951-z
   PubMed Web of Science ®Google Scholar
• Guo L, Wang Y, Yang W, et al. Molecular profiling provides clinical insights into targeted and immunotherapies as well as colorectal cancer. Prog Gastro. 2023;165(2):414–428.e7. doi:10.1053/j.gastro.2023.04.029
   PubMed Web of Science ®Google Scholar
• Xiao L, Wang Q, Peng H. Tumor-associated macrophages: new insights on their metabolic regulation and their influence in cancer immunotherapy. Front Immunol. 2023;14:1157291. doi:10.3389/fimmu.2023.1157291
   PubMedGoogle Scholar
• Zhang Y, Yang H, Zhao J, et al. Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer. J Immunother Cancer. 2021;9(2):e001364. doi:10.1136/jitc-2020-001364
   PubMed Web of Science ®Google Scholar
• Ngambenjawong C, Gustafson HH, Pun SH. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev. 2017;114:206–221. doi:10.1016/j.addr.2017.04.010
   PubMed Web of Science ®Google Scholar
• Z H, et al. CAR T-Cell therapy for the management of mantle cell lymphoma. Mol Cancer. 2023;22:1.
   PubMed Web of Science ®Google Scholar
• J H, et al. PRELP regulates cell-cell adhesion and EMT and inhibits retinoblastoma progression. Cancers. 2022;14:1.
   Web of Science ®Google Scholar
• T F, et al. Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study. BJOG. 2018;125:1.
   PubMed Web of Science ®Google Scholar
• M M, et al. Hepatic posttranscriptional network comprised of CCR4-NOT deadenylase and FGF21 maintains systemic metabolic homeostasis. Proc Natl Acad Sci USA. 2019;116:1.
   Web of Science ®Google Scholar
• CNOT7 modulates biological functions of ovarian cancer cells via AKT signaling pathway - PubMed. https://pubmed.ncbi.nlm.nih.gov/33412213/.Accessed July 3 2024.
   Google Scholar
• Y M, J L, B F, L S. MicroRNA-126-5p inhibits the migration of breast cancer cells by directly targeting CNOT7. Technol Cancer Res Treat. 2020;19:1.
   Web of Science ®Google Scholar
• L L, et al. Enhancer remodeling activates NOTCH3 signaling to confer chemoresistance in advanced nasopharyngeal carcinoma. Cell Death Dis. 2023;14:1.
   PubMed Web of Science ®Google Scholar
• K S, et al. LIN28B promotes cell invasion and colorectal cancer metastasis via CLDN1 and NOTCH3. JCI Insight. 2023;8:1.
   Web of Science ®Google Scholar
• Feng Z, Ke S, Wang C, et al. RNF125 attenuates hepatocellular carcinoma progression by downregulating SRSF1-ERK pathway. Oncogene. 2023;42(24):2017–2030. doi:10.1038/s41388-023-02710-w
   PubMed Web of Science ®Google Scholar
• Arif W, Mathur B, Saikali MF, et al. Splicing factor SRSF1 deficiency in the liver triggers NASH-like pathology and cell death. Nat Commun. 2023;14(1):551. doi:10.1038/s41467-023-35932-3
   PubMed Web of Science ®Google Scholar
• Du T, Song Y, Ray A, et al. Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma. Blood. 2023;141(21):2599–2614. doi:10.1182/blood.2022017897
   PubMed Web of Science ®Google Scholar
• Sharen G, Li X, Sun J, et al. Silencing eL31 suppresses the progression of colorectal cancer via targeting DEPDC1. J Transl Med. 2022;20(1):493. doi:10.1186/s12967-022-03663-6
   PubMed Web of Science ®Google Scholar